Orthocell (ASX:OCC) - Managing Director, Paul Anderson (left)
Managing Director, Paul Anderson (left)
Source: Orthocell
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Orthocell (OCC) appoints Samson Medical Technologies (SMT) as its exclusive distributor for Striate+ across Australia
  • Headquartered in Sydney, SMT provides innovative and clinically proven medical and cosmetic technologies across Australia and New Zealand
  • Striate+ is a dental collagen membrane used for bone and tissue regeneration procedures, and consists of both a smooth and rough side
  • The smooth side prevents gingival soft tissue growing during bone healing while the rough side helps new bone growth
  • Orthocell is up 3.60 per cent with shares trading at 57.5 cents at 12:20 pm AEST

Orthocell (OCC) has appointed Samson Medical Technologies (SMT) as its exclusive distributor for Striate+ across Australia.

Headquartered in Sydney, Samson Medical Technologies provides innovative and clinically proven medical and cosmetic technologies across Australia and New Zealand.

It has established relationships with leading plastic, reconstructive, oral and maxillofacial surgeons across Australia.

SMT will now distribute Striate+ for use in bone and soft tissue repairs. It will also undertake targeted promotion activities and initiate sales.

Founder and CEO of SMT Andrew Nutman is excited to begin working with Orthocell and distribute Striate+ across a wide range of industries.

“I am extremely excited to be working with Orthocell to distribute its Australian-made range of dental and maxillofacial collagen membranes in Australia,” Mr Nutman said.

“We look forward to working with the team at Orthocell to make Striate+ (CelGro Dental) the product of choice amongst the oral surgical and dental implant industry.”

Striate+ is a dental collagen membrane used for bone and tissue regeneration procedures. it consists of both a smooth and rough side.

The smooth side is placed facing the oral cavity to prevent gingival soft tissue growing during bone healing while the rough side is placed facing the defect to help new bone growth.

Orthocell Managing Director Paul Anderson is pleased to be working with an experienced and highly regarded company such as SMT.

“SMT is a leading distributor of innovative medical devices with an experienced team to assist in managing the market entry, promotion of distribution of Striate+,” Mr Anderson said.

“SMT is the ideal partner in our local market with established relationships with oral surgeons and a successful track record of driving market entry of high quality products.”

Orthocell was up 3.60 per cent with shares trading at 57.5 cents at 12:20 pm AEST.

OCC by the numbers
More From The Market Online

This stock provides Oz’s only HIV self-test kit – and it’s bullish on the budget

Atomo Diagnostics is the only company in Australia that provides TGA-approved HIV self-test kits. It says…

Recce Pharma heading closer to full efficacy data for flagship R327

Recce Pharma has announced the latest cohort of patients in the company's Phase I/II UTI trial…
The Market Online Video

Breaking barriers in cancer treatment: Race Oncology pioneers a new era with bisantrene

Race Oncology (ASX:RAC) has announced positive results in killing cancer cells in combination with the drug…

Optiscan agreement with Mayo Clinic aims to expedite robotic surgery

Optiscan Imaging is parterning with Mayo Clinic to develop a digital confocal laser endomicroscopic imaging system